

# Somalia

Population 2015

11 million

Estimates of TB burden*, 2015	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	7 (4.1–11)	65 (38–98)
Mortality (HIV+TB only)	0.21 (0.15–0.28)	2 (1.4–2.6)
Incidence (includes HIV+TB)	30 (19–42)	274 (177–391)
Incidence (HIV+TB only)	0.53 (0.33–0.77)	4.9 (3.1–7.1)
Incidence (MDR/RR-TB)**	3.1 (1.8–4.4)	29 (17–41)

## Estimated TB incidence by age and sex (thousands)\*, 2015

	0-14 years	> 14 years	Total
Females	2.2 (0.67–3.8)	9.3 (3.4–15)	12 (4–19)
Males	3.1 (1.8–4.3)	15 (9.8–20)	18 (12–24)
Total	5.3 (3.4–7.2)	24 (18–31)	30 (19–42)

## TB case notifications, 2015

Total cases notified	14 203
Total new and relapse	13 982
- % tested with rapid diagnostics at time of diagnosis	
- % with known HIV status	78%
- % pulmonary	77%
- % bacteriologically confirmed among pulmonary	65%

## Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2015	47% (33–73)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2015	0.25 (0.13–0.44)

## TB/HIV care in new and relapse TB patients, 2015

	Number	(%)
Patients with known HIV-status who are HIV-positive	195	2%
- on antiretroviral therapy	131	67%

Drug-resistant TB care, 2015	New cases	Previously treated cases	Total number***
Estimated MDR/RR-TB cases among notified pulmonary TB cases			1 200 (920–1 500)
Estimated % of TB cases with MDR/RR-TB	8.7% (5.9–11)	47% (29–65)	
% notified tested for rifampicin resistance	0%	10%	76
MDR/RR-TB cases tested for resistance to second-line drugs			75
Laboratory-confirmed cases		MDR/RR-TB: 75, XDR-TB: 0	
Patients started on treatment ****		MDR/RR-TB: 74, XDR-TB: 0	

Treatment success rate and cohort size	Success	Cohort
New and relapse cases registered in 2014	86%	12 903
Previously treated cases, excluding relapse, registered in 2014	59%	227
HIV-positive TB cases, all types, registered in 2014		
MDR/RR-TB cases started on second-line treatment in 2013	77%	30
XDR-TB cases started on second-line treatment in 2013		0

## TB preventive treatment, 2015

% of HIV-positive people (newly enrolled in care) on preventive treatment	34%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	

## TB financing, 2016

National TB budget (US\$ millions)	11
Funding source: 0% domestic, 100% international, 0% unfunded	

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed


# Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)




— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

## Notified cases by age group and sex, 2015




## Treatment success rate (%)



— New and relapse  
— Retreatment, excluding relapse  
— HIV-positive — MDR/RR-TB — XDR-TB

## Total budget (US\$ millions)



— Unfunded  
— Funded internationally  
— Funded domestically